Hemostemix Inc. (CVE:HEM – Get Free Report)’s share price shot up 42.9% during mid-day trading on Tuesday . The stock traded as high as C$0.11 and last traded at C$0.10. 340,639 shares traded hands during mid-day trading, an increase of 259% from the average session volume of 94,981 shares. The stock had previously closed at C$0.07.
Hemostemix Stock Up 57.1 %
The firm has a fifty day simple moving average of C$0.08 and a 200-day simple moving average of C$0.07. The company has a market cap of C$9.58 million, a PE ratio of -5.50 and a beta of 0.20.
About Hemostemix
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Featured Articles
- Five stocks we like better than Hemostemix
- Breakout Stocks: What They Are and How to Identify Them
- 3 Stocks Helping to Bring AI to Healthcare
- NYSE Stocks Give Investors a Variety of Quality OptionsÂ
- 3 Stocks Ringing in The New Year With Large Buyback Announcements
- How to Calculate Return on Investment (ROI)
- Why 2024 Was Great for Stocks—and Why 2025 Could Be Even Better
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
